Search For "phase 3 trial results of covaxin"
Updated : 3 months, 2 weeks ago IST
New Delhi [India], (ANI): Hours after Bharat Biotech announced that its vaccine Covaxin's efficacy against COVID-19 is 77.8 per cent, National Technical Advisory Group on Immunisation (NTAGI) Chief Dr NK Arora said that these results will help the vaccine get recognition from the World Healt
Updated : 3 months, 3 weeks ago IST
Hyderabad (Telangana) [India], July 3 (ANI): Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19.